Bifogade filer
Kurs
-0,84%
Likviditet
1,83 MSEK
Kalender
Est. tid* | ||
2026-05-08 | 07:00 | Bokslutskommuniké 2026 |
2026-02-03 | 07:00 | Kvartalsrapport 2026-Q3 |
2025-11-05 | 07:00 | Kvartalsrapport 2026-Q2 |
2025-08-22 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2025-08-21 | - | Årsstämma |
2025-08-08 | - | Kvartalsrapport 2026-Q1 |
2025-05-08 | - | Bokslutskommuniké 2025 |
2025-02-05 | - | Kvartalsrapport 2025-Q3 |
2024-11-06 | - | Kvartalsrapport 2025-Q2 |
2024-08-20 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2024-08-19 | - | Årsstämma |
2024-08-08 | - | Kvartalsrapport 2025-Q1 |
2024-05-14 | - | Bokslutskommuniké 2024 |
2024-02-14 | - | Kvartalsrapport 2024-Q3 |
2023-11-17 | - | Kvartalsrapport 2024-Q2 |
2023-08-18 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2023-08-17 | - | Årsstämma |
2023-08-16 | - | Kvartalsrapport 2024-Q1 |
2023-05-11 | - | Bokslutskommuniké 2023 |
2023-02-14 | - | Kvartalsrapport 2023-Q3 |
2023-02-13 | - | Kvartalsrapport 2023-Q3 |
2022-11-11 | - | Kvartalsrapport 2023-Q2 |
2022-10-26 | - | Extra Bolagsstämma 2022 |
2022-08-18 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2022-08-17 | - | Årsstämma |
2022-08-16 | - | Kvartalsrapport 2023-Q1 |
2022-05-13 | - | Bokslutskommuniké 2022 |
2022-02-16 | - | Kvartalsrapport 2022-Q3 |
2021-11-11 | - | Kvartalsrapport 2022-Q2 |
2021-08-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2021-08-18 | - | Årsstämma |
2021-08-18 | - | Kvartalsrapport 2022-Q1 |
2021-05-06 | - | Bokslutskommuniké 2021 |
2021-02-18 | - | Kvartalsrapport 2021-Q3 |
2020-11-06 | - | Kvartalsrapport 2021-Q2 |
2020-08-28 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2020-08-27 | - | Årsstämma |
2020-08-27 | - | Kvartalsrapport 2021-Q1 |
2020-05-04 | - | Bokslutskommuniké 2020 |
2020-02-05 | - | Kvartalsrapport 2020-Q3 |
2019-11-11 | - | Kvartalsrapport 2020-Q2 |
2019-08-23 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2019-08-22 | - | Årsstämma |
2019-08-22 | - | Kvartalsrapport 2020-Q1 |
2018-08-22 | - | Årsstämma |
2018-05-24 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2018-05-23 | - | Bokslutskommuniké 2018 |
2017-10-24 | - | Kvartalsrapport 2018-Q3 |
2017-08-21 | - | Kvartalsrapport 2018-Q2 |
2017-05-16 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2017-05-15 | - | Årsstämma |
2017-05-15 | - | Kvartalsrapport 2018-Q1 |
2017-02-08 | - | Bokslutskommuniké 2017 |
2016-10-25 | - | Kvartalsrapport 2017-Q3 |
2016-08-09 | - | Kvartalsrapport 2017-Q2 |
2016-05-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2016-05-13 | - | Årsstämma |
2016-05-13 | - | Kvartalsrapport 2017-Q1 |
2016-02-20 | - | Bokslutskommuniké 2016 |
2016-02-16 | - | Bokslutskommuniké 2016 |
2015-11-11 | - | Kvartalsrapport 2016-Q3 |
2015-10-09 | - | Extra Bolagsstämma 2016 |
2015-08-05 | - | Kvartalsrapport 2016-Q2 |
2015-05-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2015-05-18 | - | Årsstämma |
2015-05-18 | - | Kvartalsrapport 2016-Q1 |
2015-02-06 | - | Bokslutskommuniké 2015 |
2014-11-10 | - | Kvartalsrapport 2015-Q3 |
2014-08-13 | - | Extra Bolagsstämma 2015 |
2014-08-11 | - | Kvartalsrapport 2015-Q2 |
2014-05-13 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2014-05-12 | - | Årsstämma |
2014-05-12 | - | Kvartalsrapport 2015-Q1 |
2014-02-07 | - | Bokslutskommuniké 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
EQL Pharma AB (the "Company") today announces that two senior executives and one key employee in the Company have chosen to exercise 466,000 warrants in the Company's outstanding incentive programs for subscription of a total of 466,000 new shares.
The Company's CEO as well as one senior executive and one key employee in the Company have chosen to make full use of the opportunity to subscribe for shares by exercise of warrants in the Company's long-term incentive programs 2021/2025 I and 2021/2021 II, respectively, which were resolved by the annual general meeting in August 2021 and the extraordinary general meeting in December 2021, respectively. A total of 466,000 warrants have been exercised in both programs, each of which entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 72.05 and SEK 67.50, respectively, per share. As a result, the Company will receive approximately SEK 31.8 million in cash.
To finance the share subscription, these warrant holders have sold in total 345,642 shares at a value of approximately SEK 28.0 million. The sale of the shares was carried out through DNB Carnegie Investment Bank (publ) in the market. To facilitate the transaction, one of the Company's major shareholders has lent 345,642 shares in the Company to these warrant holders, who have undertaken to return these shares without delay as soon as practically possible after the share subscription has been registered by the Swedish Companies Registration Office.
The subscription period in the warrant programs runs until 30 September 2025 and participants who have not yet subscribed for shares in accordance with the above can therefore choose to subscribe for additional shares until this date.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com